Transform Your Metabolic Health & Longevity by Knowing Your Unique Biology | Dr. Michael Snyder

KEYPOINTS

• 01

  A healthy glucose response is a brief, modest spike

  Snyder, a Stanford geneticist, says a normal post-meal spike returns to baseline within about 30–60 minutes. Fasting glucose for most people is around 90. 'Time in range' is a simple target: 70–140 mg/dL for healthy people, 70–180 for diabetics. It correlates strongly with hemoglobin A1c (6.5% or higher is diabetes, 5.7–6.4% is prediabetes), but a CGM shows what's happening in real time.

• 02

  Many 'normal' people spike like diabetics

  When Snyder's lab put CGMs on normal, prediabetic and diabetic people, they defined 'glucotypes'. Some people with no diagnosis spiked as badly as diabetics and had no idea. Glycemic response is also more personal than the glycemic index suggests: most people spike to white rice, but individual responses to specific foods vary a lot.

• 03

  Type 2 diabetes is several different problems

  Snyder's lab subdivides glucose dysregulation into muscle insulin resistance, liver insulin resistance, beta-cell defects (making insulin but not releasing it from the pancreas) and incretin defects. Muscle-resistant people spike to potatoes and pasta, while insulin-sensitive people don't. People with beta-cell defects also spike to potatoes. The shape of a glucose curve from an over-the-counter CGM can already predict muscle insulin resistance fairly accurately.

• 04

  Your subtype determines what works

  Snyder himself has a beta-cell defect. He switched from running to weight training about nine years ago and gained 10 lb of muscle, verified by about 20 whole-body MRIs, yet his glucose control didn't improve, because muscle wasn't his problem. He didn't respond to metformin. For muscle-resistant people, building muscle and training in the morning appear to give better glucose benefits, though exercise at any time beats none.

• 05

  GLP-1 drugs worked dramatically for him, with trade-offs

  Snyder's A1c was 8.4%. A lower-dose GLP-1 drug brought it to about 6.4–6.5%, and after he switched to Mounjaro because of modest nausea, it fell to 5.7%. His fat 'evaporated' and mild fatty liver disappeared. He lifts every day, alternating light, heavy and skill days, but still lost some muscle and strength after an injury. He felt gaunt, so he now doses less often than weekly on the lowest dose. He notes that some people use low doses from compounding pharmacies, which the pharmaceutical companies dislike.

• 06

  Visceral fat stresses organs, especially beta cells

  Snyder isn't an expert here, but he says fat around organs, such as fatty liver, clearly isn't good. He thinks the pancreas, and beta cells in particular, may be especially sensitive to that fat-related stress.

• 07

  Fiber effects are personal

  In an 18-person crossover study, people took 10, then 20, then 30 g per day of arabinoxylan (the fiber family found in psyllium/Metamucil-type products) or inulin, with washouts in between. On average, arabinoxylan lowered LDL cholesterol by about 25%, but some people saw no change even at 30 g, while inulin lowered theirs. Neither fiber affected glucose. Recommended intake is at least 25 g a day for women and 35 g for men, but people typically get 12–15 g.

• 08

  Organs age at different rates: 'ageotypes'

  After following about 109 people for more than 12 years with deep blood profiling, Snyder's group sees distinct aging patterns: cardio, metabolic, liver, kidney, immune, or several at once. Like a car where certain parts wear first, these patterns can be acted on. People who lost weight or exercised improved their metabolic ageotype. A company he helped commercialize, Iolo, profiles 650 metabolites from a mailed drop of blood. He notes that 95% of users improved their markers, which isn't the same as getting younger.

• 09

  A whole-body MRI baseline helps when you track change over time

  High-resolution scans almost always find nodules, which is why many doctors discourage them. Snyder argues the question is whether nodules grow, and you can't know without a baseline. None of his nine nodules are growing. His group has caught early problems from shifts in an individual's own values, such as liver enzymes, that standard ranges would miss.